Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study
Background Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa is highly effective, but can be associated with frequent side-effects. We investigated the safety and efficacy of an interferon-free regimen for treatment of acute HCV infection.
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
The lancet. Infectious diseases
Year: 2016, Jahrgang: 17, Heft: 2, Pages: 215-222 |
| ISSN: | 1474-4457 |
| DOI: | 10.1016/S1473-3099(16)30408-X |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/S1473-3099(16)30408-X Verlag, Volltext: https://linkinghub.elsevier.com/retrieve/pii/S147330991630408X 
|
| Verfasserangaben: | Katja Deterding, Christoph D Spinner, Eckart Schott, Tania M Welzel, Guido Gerken, Hartwig Klinker, Ulrich Spengler, Johannes Wiegand, Julian Schulze zur Wiesch, Anita Pathil, Markus Cornberg, Andreas Umgelter, Caroline Zöllner, Stefan Zeuzem, Armin Papkalla, Kristina Weber, Svenja Hardtke, Heiko von der Leyen, Armin Koch, Dorothee von Witzendorff, Michael P Manns, Heiner Wedemeyer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1582121354 | ||
| 003 | DE-627 | ||
| 005 | 20230427193140.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181019r20172016xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(16)30408-X |2 doi | |
| 035 | |a (DE-627)1582121354 | ||
| 035 | |a (DE-576)512121354 | ||
| 035 | |a (DE-599)BSZ512121354 | ||
| 035 | |a (OCoLC)1341019890 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Deterding, Katja |d 1973- |e VerfasserIn |0 (DE-588)132829037 |0 (DE-627)527119601 |0 (DE-576)299442802 |4 aut | |
| 245 | 1 | 0 | |a Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV) |b an open-label, single-arm, phase 2 study |c Katja Deterding, Christoph D Spinner, Eckart Schott, Tania M Welzel, Guido Gerken, Hartwig Klinker, Ulrich Spengler, Johannes Wiegand, Julian Schulze zur Wiesch, Anita Pathil, Markus Cornberg, Andreas Umgelter, Caroline Zöllner, Stefan Zeuzem, Armin Papkalla, Kristina Weber, Svenja Hardtke, Heiko von der Leyen, Armin Koch, Dorothee von Witzendorff, Michael P Manns, Heiner Wedemeyer |
| 264 | 1 | |c 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 28 October 2016 | ||
| 500 | |a Gesehen am 19.10.2018 | ||
| 520 | |a Background Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa is highly effective, but can be associated with frequent side-effects. We investigated the safety and efficacy of an interferon-free regimen for treatment of acute HCV infection. | ||
| 534 | |c 2016 | ||
| 700 | 1 | |a Pathil-Warth, Anita |d 1981- |e VerfasserIn |0 (DE-588)132644304 |0 (DE-627)524715890 |0 (DE-576)260118915 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Infectious diseases |d New York, NY : Elsevier, 2001 |g 17(2017), 2, Seite 215-222 |h Online-Ressource |w (DE-627)34191200X |w (DE-600)2070985-7 |w (DE-576)121466701 |x 1474-4457 |7 nnas |a Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV) an open-label, single-arm, phase 2 study |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:2 |g pages:215-222 |g extent:8 |a Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV) an open-label, single-arm, phase 2 study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1473-3099(16)30408-X |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://linkinghub.elsevier.com/retrieve/pii/S147330991630408X |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181019 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 132644304 |a Pathil-Warth, Anita |m 132644304:Pathil-Warth, Anita |d 910000 |d 910100 |e 910000PP132644304 |e 910100PP132644304 |k 0/910000/ |k 1/910000/910100/ |p 10 | ||
| 999 | |a KXP-PPN1582121354 |e 3029205495 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Katja","family":"Deterding","display":"Deterding, Katja","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Pathil-Warth, Anita","given":"Anita","family":"Pathil-Warth"}],"name":{"displayForm":["Katja Deterding, Christoph D Spinner, Eckart Schott, Tania M Welzel, Guido Gerken, Hartwig Klinker, Ulrich Spengler, Johannes Wiegand, Julian Schulze zur Wiesch, Anita Pathil, Markus Cornberg, Andreas Umgelter, Caroline Zöllner, Stefan Zeuzem, Armin Papkalla, Kristina Weber, Svenja Hardtke, Heiko von der Leyen, Armin Koch, Dorothee von Witzendorff, Michael P Manns, Heiner Wedemeyer"]},"physDesc":[{"extent":"8 S."}],"language":["eng"],"title":[{"title":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV)","title_sort":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV)","subtitle":"an open-label, single-arm, phase 2 study"}],"recId":"1582121354","note":["Available online 28 October 2016","Gesehen am 19.10.2018"],"origin":[{"dateIssuedDisp":"2017","dateIssuedKey":"2017"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"title":[{"partname":"Infectious diseases","title_sort":"lancet","title":"The lancet"}],"language":["eng"],"note":["Gesehen am 22.09.2021"],"recId":"34191200X","disp":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV) an open-label, single-arm, phase 2 studyThe lancet. Infectious diseases","titleAlt":[{"title":"The lancet <London> / Infectious diseases"}],"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.2001 -"],"part":{"issue":"2","text":"17(2017), 2, Seite 215-222","extent":"8","volume":"17","pages":"215-222","year":"2017"},"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"2001-","dateIssuedKey":"2001","publisherPlace":"New York, NY ; London","publisher":"Elsevier ; Lancet Publ. Group"}],"id":{"zdb":["2070985-7"],"issn":["1474-4457"],"eki":["34191200X"]}}],"id":{"eki":["1582121354"],"doi":["10.1016/S1473-3099(16)30408-X"]}} | ||
| SRT | |a DETERDINGKLEDIPASVIR2017 | ||